Skip to Main Content

Author Details

Sunkyu Kim
Korea University
2000
46
28
Ying Ding (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37551911Biomedical relation extraction with knowledge base-refined weak supervision.Database (Oxford)2023
36385925Discovery of 5,7-Dihydro-6<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-6-ones as Highly Selective CDK2 Inhibitors.ACS Med Chem Lett2022
34083538Crowdsourced mapping of unexplored target space of kinase inhibitors.Nat Commun2021
33600552Correction: The deubiquitylase USP9X controls ribosomal stalling.J Cell Biol2021
33507233The deubiquitylase USP9X controls ribosomal stalling.J Cell Biol2021
34868947Deep-Learning-Based Natural Language Processing of Serial Free-Text Radiological Reports for Predicting Rectal Cancer Patient Survival.Front Oncol2021
34636321USP28 deletion and small-molecule inhibition destabilizes c-MYC and elicits regression of squamous cell lung carcinoma.Elife2021
34252937Predicting mechanism of action of novel compounds using compound structure and transcriptomic signature coembedding.Bioinformatics2021
31501885BioBERT: a pre-trained biomedical language representation model for biomedical text mining.Bioinformatics2020
31680157ChimerDB 4.0: an updated and expanded database of fusion genes.Nucleic Acids Res2020
32657401Improved survival analysis by learning shared genomic information from pan-cancer data.Bioinformatics2020
32591513Building a PubMed knowledge graph.Sci Data2020
32292577Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models.Oncotarget2020
31116384ReSimNet: drug response similarity prediction using Siamese neural networks.Bioinformatics2019
29368597Deep learning of mutation-gene-drug relations from the literature.BMC Bioinformatics2018
30443290The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models.Oncotarget2018
29697361Mut2Vec: distributed representation of cancerous mutations.BMC Med Genomics2018
29562737Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.J Med Chem2018
29560824In silico drug combination discovery for personalized cancer therapy.BMC Syst Biol2018
27899563ChimerDB 3.0: an enhanced database for fusion genes from cancer transcriptome and literature data mining.Nucleic Acids Res2017
28296398Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer.J Med Chem2017
28151717Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.Clin Cancer Res2017
29045389Molecular basis of USP7 inhibition by selective small-molecule inhibitors.Nature2017
27986745Dual <i>ALK</i> and <i>CDK4/6</i> Inhibition Demonstrates Synergy against Neuroblastoma.Clin Cancer Res2017
27729458Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma.Clin Cancer Res2017
27074804BRONCO: Biomedical entity Relation ONcology COrpus for extracting gene-variant-disease-drug relations.Database (Oxford)2016
27760149BEST: Next-Generation Biomedical Entity Search Tool for Knowledge Discovery from Biomedical Literature.PLoS One2016
27485446HiPub: translating PubMed and PMC texts to networks for knowledge discovery.Bioinformatics2016
26337082Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.Oncotarget2015
24362935Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.Nat Med2014
25344755Cyclin C is a haploinsufficient tumour suppressor.Nat Cell Biol2014
25002028CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.Cancer Cell2014
25028469Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo.Mol Cancer Ther2014
23842682An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).Cancer Discov2013
24045179Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.Clin Cancer Res2013
24900493Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors.ACS Med Chem Lett2012
210388534-(Pyrazol-4-yl)-pyrimidines as selective inhibitors of cyclin-dependent kinase 4/6.J Med Chem2010
16724057Validating cancer drug targets.Nature2006
15894405Correlation between the activities of alpha-helical antimicrobial peptides and hydrophobicities represented as RP HPLC retention times.Peptides2005
15126329Depletion of methionine aminopeptidase 2 does not alter cell response to fumagillin or bengamides.Cancer Res2004
14571120Synergistic inhibitory effect of cationic peptides and antimicrobial agents on the growth of oral streptococci.Caries Res2003
14499271In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines.Peptides2003
14534293Proteomics-based target identification: bengamides as a new class of methionine aminopeptidase inhibitors.J Biol Chem2003
12234496Cloning, expression, and characterization of a soluble calcium-activated nucleotidase, a human enzyme belonging to a new family of extracellular nucleotidases.Arch Biochem Biophys2002
11682065Structural study of novel antimicrobial peptides, nigrocins, isolated from Rana nigromaculata.FEBS Lett2001
10691971Ligand binding inhibitors of A1 adenosine receptor from Rana rugosa are phospholipase A2s.Eur J Biochem2000
  • 1 - 46 of 46

Recommended Authors

College of Medicine, The Ohio State University
Career Start Year 2018
Number of shared co-authors 0
University of Helsinki
Career Start Year 2016
Number of shared co-authors 4
College of Materials and Chemical Engineering, Zhengzhou University of Light Industry
Career Start Year 2015
Number of shared co-authors 0
Princess Margaret Cancer Centre, University Health Network, University Ave.
Career Start Year 2013
Number of shared co-authors 0
Centre Hospitalier Universitaire Sainte-Justine Research Centre
Career Start Year 2011
Number of shared co-authors 0
Oregon State University
Career Start Year 2011
Number of shared co-authors 0
Duke University School of Medicine
Career Start Year 2011
Number of shared co-authors 0
University of Colorado Anschutz Medical Campus
Career Start Year 2011
Number of shared co-authors 3
University Institute of Pharma Sciences, Chandigarh University
Career Start Year 2011
Number of shared co-authors 0
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 0
the University of Texas MD Anderson Cancer Center
Career Start Year 2009
Number of shared co-authors 1
Institute of Cancer and Genomic Sciences, University of Birmingham
Career Start Year 2008
Number of shared co-authors 0
University of Helsinki
Career Start Year 2007
Number of shared co-authors 9
Quantitative Biomedical Research Center
Career Start Year 2007
Number of shared co-authors 8
University of Colorado Anschutz Medical Campus
Career Start Year 2006
Number of shared co-authors 5
Jilin University
Career Start Year 2005
Number of shared co-authors 0
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2004
Number of shared co-authors 1
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 1
St. Jude Children's Research Hospital
Career Start Year 2003
Number of shared co-authors 3
National Center for Advancing Translational Sciences, National Institutes of Health
Career Start Year 2003
Number of shared co-authors 3
Meyer Cancer Center
Career Start Year 2002
Number of shared co-authors 3
Institute for Data Science and Computing, University of Miami
Career Start Year 1998
Number of shared co-authors 3
Kaohsiung Medical University
Career Start Year 1998
Number of shared co-authors 0
Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences
Career Start Year 1998
Number of shared co-authors 0
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 1
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Career Start Year 1996
Number of shared co-authors 1
Middle East Technical University
Career Start Year 1994
Number of shared co-authors 0
Weill-Cornell School of Medicine
Career Start Year 1989
Number of shared co-authors 1
Broad Institute of MIT and Harvard
Career Start Year 1989
Number of shared co-authors 15
Asan Medical Center, University of Ulsan College of Medicine
Career Start Year 1988
Number of shared co-authors 0

Collaborators

Korea University
Co-authored papers 13
Co-authored papers 5
Korea University College of Medicine
Co-authored papers 5
Co-authored papers 5
Huntsman Cancer Institute, The University of Utah
Co-authored papers 5
H3 Biomedicine Inc.
Co-authored papers 4
Children's Hospital of Philadelphia, USA. [2] Center for Childhood Cancer Research
Co-authored papers 3
Korea Advanced Institute of Science and Technology
Co-authored papers 3
Children's Hospital of Philadelphia
Co-authored papers 2
Co-authored papers 2
Dana-Farber Cancer Institute
Co-authored papers 2
Perelman School of Medicine at the University of Pennsylvania
Co-authored papers 2
Perelman School of Medicine, University of Pennsylvania
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2
Dana-Farber Cancer Institute
Co-authored papers 2
Harvard Medical School
Co-authored papers 1
University of Pennsylvania Perelman School of Medicine
Co-authored papers 1
Verily Life Sciences LLC
Co-authored papers 1
Children's Hospital of Philadelphia
Co-authored papers 1
Peking University
Co-authored papers 1
Co-authored papers 1
Co-authored papers 1
University of Texas at Austin
Co-authored papers 1
University of Parma
Co-authored papers 1
Dana Farber Cancer Institute
Co-authored papers 1
University of Texas at Austin
Co-authored papers 1
Co-authored papers 1
Janssen Research and Development LLC
Co-authored papers 1